Myriant Technologies, a Quincy, MA-based developer of biochemicals, revealed its intention to raise $125 million in an initial public offering, according to documents filed with the SEC. The company plans to put the proceeds toward completing a plant in Louisiana, as well as working capital, research and development, and general corporate purposes. It reported a $16 million net loss on $14 million in revenue for 2010. In January Myriant brought in $60 million in equity financing from PTT Chemical Public Company.
